COST-EFFECTIVENESS OF GENOTHERAPEUTIC DRUG NEOVASCULGEN I N TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA
Chronic lower limb ischemia (CLLI) is a severe disease with high level of disability. Genotherapy is a perspective way of treating this diseases. Use of Neovasculgen, a novel VEGF165-based therapeutic product in treatment of CLLI increase possibilities of treatment of this disease. There is need to address economical effectiveness of its use. The Markov state transition model of CLLI progression in case of treatment with Neovasculgen treatment and without was constructed and calibrated from 2-years clinical trial data of the drug. Number of QALY saved was used as primary effectiveness indicator. The treatment with Neovasculgen increased number of QALY by 2.66 years, discounted total cost of treatment was 472 thousand rubles lower per patient in Neovasculgen group. The strategy of using Neovasculgen was dominating as it is both cost saving and effective.